1 ent (aspirin/clopidogrel vs aspirin/placebo;
double-blinded).
2 and 2, allocation to DSM265 and placebo was
double-blinded.
3 ients were assigned via central computerized
double-blind 1:1 randomization to receive either a singl
4 We did a phase 2, randomised,
double-blind,
active-controlled, non-inferiority study.
5 In this randomised,
double-blind,
active-controlled, phase 3 equivalence tri
6 vs pravastatin for Dyslipidemia) randomised,
double-blind,
active-controlled, phase 4 trial (INTREPID
7 nters were randomized (1:1 ratio) to receive
double-blind adjunctive safinamide or placebo for 24 wee
8 We did a
double-blind,
allocation concealed, randomised, placebo-
9 ients completed study drug dosing during the
double-blind and open-label phases, respectively.
10 This
double-blind and placebo (or low-dose)-controlled random
11 We approached this question by applying
double-blind bihemispheric transcranial direct current s
12 Randomized,
double-blind clinical trial comparing oral cephalexin an
13 A randomized, placebo-controlled,
double-blind clinical trial conducted in Isala Zwolle, t
14 We conducted a randomized
double-blind clinical trial in adults with NDD-CKD and i
15 atment of actinic keratosis in a randomized,
double-blind clinical trial involving 131 participants.
16 The use of a placebo and of
double-blind control groups in surgery CTs would improve
17 A new randomized,
double-blind controlled study has found that playing a v
18 a secondary analysis of MS-STAT, a 24-month,
double-blind,
controlled trial of patients with SPMS don
19 PAM JNJ-39393406 (100 mg b.i.d.) or placebo (
double-blind,
counter-balanced).
20 We performed a
double-blind crossover challenge of 59 individuals on a
21 a novel endogenous pathway.In a randomized,
double-blind crossover study, 16 healthy individuals wer
22 , ascending dose cohorts underwent a further
double-blind crossover, placebo-controlled oral gluten c
23 In this randomized,
double-blind,
crossover study, twelve normoglycaemic men
24 We did a randomised, placebo-controlled,
double-blind,
crossover trial of a quadpill-a single cap
25 ealthy male subjects completed a randomized,
double-blinded,
crossover-design study in which they con
26 ment with 20 mg vortioxetine or placebo in a
double-blind design.
27 METHODS AND In a
double-blinded design, 40 patients with moderate-severe
28 e conducted two phase 1, placebo-controlled,
double-blind,
dose-escalation trials of an rVSV-based va
29 In this single-site,
double-blind,
double-dummy clinical trial, we randomly a
30 osed Triple Therapy) trial was a randomized,
double-blind,
double-dummy study comparing 24 weeks of o
31 In this
double-blind,
double-dummy trial, we enrolled post-menop
32 In this international, randomised,
double-blind,
double-dummy, phase 3 trial, we recruited
33 We undertook this randomised,
double-blind,
efficacy, immunogenicity, and safety study
34 erlands, and Sweden), with optional 12-month
double-blind extensions.
35 s (n=7513) were randomized in a double-dummy
double-blind fashion to either extended-duration oral be
36 l maintenance doses of 300 or 3000 mg/d in a
double-blinded fashion.
37 which was defined as the negativization of a
double-blind food challenge results at 12, 24, and 36 mo
38 2 randomized, crossover, controlled studies (
double-blinded for the supplements), each on 16 healthy
39 We conducted a
double-blind,
household-cluster-randomized, placebo-cont
40 ts with mild-to-moderate AD in a randomized,
double-blind,
intraindividual comparison of 3 approved a
41 tients were randomized equally to receive 15
double-blind intravenous infusions of adjunctive lanicem
42 :1 using an interactive response system to a
double-blind investigational product, and stratified by
43 men and >/=6 mg/dl in women) randomized in a
double-blinded manner to receive placebo or allopurinol
44 This randomized,
double-blind,
multicenter study evaluated the effects of
45 We conducted a randomized,
double-blind,
multicenter trial of RIV4 (45 mug of recom
46 Prospective,
double-blind,
multicenter, randomized controlled study.
47 In this
double-blind,
multicenter, randomized, parallel-group st
48 We did a randomised,
double-blind,
multicentre phase 2 trial of a combination
49 This randomised,
double-blind,
multicentre, phase 3 trial was done in 87
50 In this randomised,
double-blind,
multicentre, placebo-controlled, non-infer
51 We did a
double-blind,
multicentre, placebo-controlled, randomise
52 Pancreatic Cancer (ViP) trial was a phase 2
double-blind,
multicentre, randomised placebo-controlled
53 In this
double-blind,
multicentre, randomised trial (GEMINI-ACS-
54 In this
double-blind,
multicentre, randomised, placebo-controlle
55 This randomised,
double-blind,
multiperiod, phase 3 trial was done at 38
56 METHOD: In a 16-week,
double-blind,
multisite comparison study, 142 participan
57 A randomized,
double-blind,
multisite placebo-controlled trial conduct
58 with meropenem in a multinational, phase 3,
double-blind,
non-inferiority trial (REPROVE).
59 In this phase 3, randomised,
double-blind,
non-inferiority trial, patients from 185 e
60 In a single-center,
double-blind,
noninferiority trial involving adults with
61 METHOD: In an exploratory
double-blind parallel-group trial, patients with schizop
62 This was a 12-mo,
double-blind,
parallel design, placebo-controlled, rando
63 ge intestinal mucosa in humans.A randomized,
double-blind,
parallel-design trial was conducted in 38
64 iDiet was a 24-month randomised, controlled,
double-blind,
parallel-group, multicentre trial (11 site
65 In this randomised,
double-blind,
parallel-group, phase 3 trial done at 152
66 For this
double-blind,
parallel-group, randomised, controlled tri
67 Single-center,
double-blind,
parallel-group, randomized clinical trial
68 This randomised, controlled,
double-blind,
parallel-group, superiority trial was done
69 nting 4,029 [alirocumab] and 2,114 [control]
double-blind patient-years' exposure).
70 I disorder (6.3% compared with 1.6%) in the
double-blind period.
71 zed to asenapine or placebo treatment in the
double-blind period.
72 e to recurrence of any mood event during the
double-blind period.
73 le-blind phase for 8 weeks and a randomised,
double-blind phase (parts 1 and 2, reported here) for 12
74 1666 patients randomized into 1 of 5 12-week
double-blind phase 2 parent studies completed a parent s
75 ASPIRE consisted of an open-label,
double-blind phase for 8 weeks and a randomised, double-
76 olerated, with similar adverse events in the
double-blind phase to placebo.
77 During the
double-blind phase, five (33%) patients assigned to BIIB
78 1.9%) discontinued from the study during the
double-blind phase.
79 received DBS implantation and completed the
double-blind phase.
80 ere reported in the BIIB074 group during the
double-blind phase.
81 to BIIB074 or placebo for up to 28 days in a
double-blind phase.
82 om baseline) averaged over months 4-6 of the
double-blind phase.
83 In this randomised, regimen-controlled,
double-blind,
phase 2 trial, we enrolled adult patients
84 In this randomised,
double-blind,
phase 2 trial, we recruited patients aged
85 In this randomised, placebo-controlled,
double-blind,
phase 2 trial, women aged 18 years or olde
86 In this randomized,
double-blind,
phase 3 study, we assigned 3396 patients w
87 We did a randomised,
double-blind,
phase 3 trial in patients with advanced or
88 this 6-month randomized, placebo-controlled,
double-blind,
phase 3 trial, we randomly assigned 395 pa
89 In this randomised,
double-blind,
phase 3 trial, we recruited patients aged
90 In this randomised,
double-blind,
phase 3b trial, we enrolled adults aged 18
91 ORAL Strategy was a 1 year,
double-blind,
phase 3b/4, head-to-head, non-inferiority,
92 Patients and Methods This randomized,
double-blind,
phase III study enrolled patients with his
93 Patients and Methods In this multicenter,
double-blind,
phase III trial, patients were randomly as
94 tly greater reduction from baseline than the
double-blind placebo in the NRS (-23%, 95% CI -45 to -1;
95 gnetic resonance imaging (fMRI) in a 2-drug,
double-blind placebo-controlled crossover design conduct
96 In a
double-blind placebo-controlled crossover design, the im
97 METHOD: In a
double-blind placebo-controlled design, 46 unmedicated d
98 capture and report clinical observations in
double-blind placebo-controlled food challenges (DBPCFC)
99 In Experiment 1, a
double-blind placebo-controlled pharmacology study, we m
100 mg daily or matching placebo in a randomised
double-blind placebo-controlled phase.
101 stemic allergen-specific IgE, we performed a
double-blind placebo-controlled pilot trial in which bir
102 Infants born to women who participated in a
double-blind placebo-controlled RCT in 2011 and 2012 on
103 In a randomized
double-blind placebo-controlled study, 56 patients with
104 alyzed data from 1092 patients enrolled in a
double-blind placebo-controlled trial to evaluate the ef
105 Purpose To determine, in a multicenter
double-blinded placebo-controlled trial, whether maximal
106 including 12 patients; a phase 3 randomized,
double blind,
placebo controlled study involving 186 pat
107 (Randomized,
Double-Blind,
Placebo Controlled Study of the Short Term
108 In a
double-blind,
placebo-controlled between-subject design,
109 set of cord blood samples from a randomized,
double-blind,
placebo-controlled clinical trial (the Vit
110 We performed a multicenter, randomized,
double-blind,
placebo-controlled clinical trial.
111 Randomized,
double-blind,
placebo-controlled clinical trial.
112 f rural Bangladeshi children from 2 previous
double-blind,
placebo-controlled cluster-randomized tria
113 In a randomized,
double-blind,
placebo-controlled crossover study of indi
114 We performed a randomized,
double-blind,
placebo-controlled crossover study with si
115 kU/L for each food, or both, and a positive
double-blind,
placebo-controlled food challenge at 500 m
116 lication for 12 months, patients underwent a
double-blind,
placebo-controlled food challenge to estab
117 n 22 patients with peanut allergy undergoing
double-blind,
placebo-controlled food challenge to peanu
118 n = 221) had peanut sensitivity and positive
double-blind,
placebo-controlled food challenges to an e
119 allergy (secondary outcome) was confirmed by
double-blind,
placebo-controlled food challenges.
120 In two
double-blind,
placebo-controlled immunotherapy studies,
121 t study consists of a randomized, crossover,
double-blind,
placebo-controlled laboratory study of IBU
122 Patients originated from the randomized,
double-blind,
placebo-controlled OmegAD study, in which
123 onducted in the United States, followed by a
double-blind,
placebo-controlled part B in East Africa.
124 To this end, we combined
double-blind,
placebo-controlled pharmacology [D2 recept
125 In this multicentre, randomised,
double-blind,
placebo-controlled phase 2 study (BERIL-1)
126 In this randomised,
double-blind,
placebo-controlled phase 2 study, we enrol
127 In this single-centre, randomised,
double-blind,
placebo-controlled phase 2 trial, healthy
128 We did a randomised,
double-blind,
placebo-controlled phase 2b trial, compris
129 cacy in Nonmetastatic RCC) was a randomized,
double-blind,
placebo-controlled phase 3 clinical trial
130 A
double-blind,
placebo-controlled pilot trial assessed sa
131 We did a randomised,
double-blind,
placebo-controlled pilot trial at a single
132 Double-blind,
placebo-controlled randomized trial (April
133 A
double-blind,
placebo-controlled randomized trial with c
134 This multicenter,
double-blind,
placebo-controlled RCT was powered on a 5%
135 analysis of the results from the randomised,
double-blind,
placebo-controlled SIROCCO and CALIMA phas
136 This randomized,
double-blind,
placebo-controlled study (TL7116958) was c
137 A multicenter, randomized,
double-blind,
placebo-controlled study evaluated 3 regim
138 In X-ACT, a phase III,
double-blind,
placebo-controlled study, CSU patients (18
139 that reduces chorea, was well tolerated in a
double-blind,
placebo-controlled study.
140 d, multicenter, prospective, 1:1 randomized,
double-blind,
placebo-controlled study.
141 magnetic resonance imaging to a randomized,
double-blind,
placebo-controlled trial (RCT) of antidepr
142 This randomized,
double-blind,
placebo-controlled trial assessed the effe
143 In this randomised,
double-blind,
placebo-controlled trial at 590 sites in 4
144 We performed our study as a randomized,
double-blind,
placebo-controlled trial by training other
145 METHODS AND TIME was a randomized,
double-blind,
placebo-controlled trial comparing 150 mil
146 Part 1 consisted of a randomised,
double-blind,
placebo-controlled trial done over 18 mont
147 We conducted a phase 2, randomized,
double-blind,
placebo-controlled trial in 27 centers acr
148 METHOD: This 6-week, randomized,
double-blind,
placebo-controlled trial included patients
149 nt Sertraline Trial (CAST) was a randomized,
double-blind,
placebo-controlled trial involving 201 pat
150 We conducted a randomized,
double-blind,
placebo-controlled trial involving 27,564
151 We conducted a randomized,
double-blind,
placebo-controlled trial involving 30,449
152 We conducted a multicenter, randomized,
double-blind,
placebo-controlled trial involving patient
153 We conducted a randomized,
double-blind,
placebo-controlled trial of amitriptyline
154 esistance Intervention After Stroke trial, a
double-blind,
placebo-controlled trial of pioglitazone f
155 We conducted a randomized,
double-blind,
placebo-controlled trial of pregabalin in
156 This randomized,
double-blind,
placebo-controlled trial recruited patient
157 hysicians' Health Study II was a randomized,
double-blind,
placebo-controlled trial testing multivita
158 Vitamin D Assessment Study is a randomized,
double-blind,
placebo-controlled trial that recruited pa
159 This PreSERVE-AMI (Phase 2, randomized,
double-blind,
placebo-controlled trial) represents the l
160 n this prospective, multicenter, randomized,
double-blind,
placebo-controlled trial, 96 HT recipients
161 For this international, multicentre,
double-blind,
placebo-controlled trial, adult patients (
162 In this multicentre, randomised,
double-blind,
placebo-controlled trial, adults (>/=18 ye
163 In this randomised,
double-blind,
placebo-controlled trial, adults with pred
164 of asthma, were included in the randomized,
double-blind,
placebo-controlled trial, comprising 3 yea
165 In this single-centre, randomised,
double-blind,
placebo-controlled trial, patients with mo
166 In this phase 2, randomized,
double-blind,
placebo-controlled trial, we compared subc
167 In this randomized,
double-blind,
placebo-controlled trial, we investigated
168 In this randomised,
double-blind,
placebo-controlled trial, we randomly allo
169 In this multicenter,
double-blind,
placebo-controlled trial, we randomly assi
170 In a preregistered, randomized,
double-blind,
placebo-controlled trial, we tested the ef
171 doxycyline in a pre-registered, randomised,
double-blind,
placebo-controlled trial.
172 were pooled from two phase III, randomized,
double-blind,
placebo-controlled trials of IFN-gamma-1b
173 Long-Term Therapy (XPORT) was a randomized,
double-blind,
placebo-controlled withdrawal study that i
174 We conducted a randomized,
double-blind,
placebo-controlled, 24-week trial of imati
175 A randomized
double-blind,
placebo-controlled, 3-parallel-group study
176 In a
double-blind,
placebo-controlled, between-subject design
177 t functional magnetic resonance imaging in a
double-blind,
placebo-controlled, crossover design to de
178 hree time points in this baseline-corrected,
double-blind,
placebo-controlled, crossover study.
179 We conducted a phase I, randomized,
double-blind,
placebo-controlled, dose-escalating study
180 We did a phase 2, randomised,
double-blind,
placebo-controlled, dose-escalation trial
181 as examined in a 3-site, 8-week, randomized,
double-blind,
placebo-controlled, fixed-dose trial using
182 This randomized,
double-blind,
placebo-controlled, multicenter study eval
183 We did a phase 3, randomised,
double-blind,
placebo-controlled, multicentre study (REG
184 This was a phase 2, randomised,
double-blind,
placebo-controlled, multicentre study of e
185 In this phase 3, randomised,
double-blind,
placebo-controlled, multicentre study, pat
186 The BELLE-2 trial was a randomised,
double-blind,
placebo-controlled, multicentre study.
187 We conducted a phase 1b, multicenter,
double-blind,
placebo-controlled, multiple-ascending-dos
188 We conducted a phase 2, multicenter,
double-blind,
placebo-controlled, multiple-ascending-dos
189 In this randomised,
double-blind,
placebo-controlled, non-inferiority trial,
190 rom 3 phase IIB and 4 phase IIIA randomized,
double-blind,
placebo-controlled, parallel group, multic
191 In this 12-week,
double-blind,
placebo-controlled, parallel-group trial,
192 In this multicenter, randomized,
double-blind,
placebo-controlled, parallel-group trial,
193 We did a randomised,
double-blind,
placebo-controlled, parallel-group, multic
194 We did two randomised,
double-blind,
placebo-controlled, phase 1 studies at 12
195 The study was a 12-week,
double-blind,
placebo-controlled, phase 2 trial of patie
196 This randomised,
double-blind,
placebo-controlled, phase 2 trial was done
197 In the multicentre, randomised,
double-blind,
placebo-controlled, phase 3 FREEDOM trial,
198 This multicentre, randomised,
double-blind,
placebo-controlled, phase 3 study was done
199 This randomised,
double-blind,
placebo-controlled, phase 3 trial (CONTINU
200 RADIANT-4 is a multicentre, randomised,
double-blind,
placebo-controlled, phase 3 trial done in
201 Patients were eligible for this randomised,
double-blind,
placebo-controlled, phase 3 trial if they
202 In this
double-blind,
placebo-controlled, phase 3 trial, we rand
203 In this randomised,
double-blind,
placebo-controlled, phase 3 trial, we recr
204 In this randomised,
double-blind,
placebo-controlled, phase 3 trial, we recr
205 We conducted a randomized,
double-blind,
placebo-controlled, phase 3, crossover tri
206 This prospective,
double-blind,
placebo-controlled, phase IIb, parallel, f
207 A 4-year,
double-blind,
placebo-controlled, population-based rando
208 Double-blind,
placebo-controlled, randomized clinical tr
209 METHOD: In a
double-blind,
placebo-controlled, randomized clinical tr
210 nical Trial), an international, multicenter,
double-blind,
placebo-controlled, randomized clinical tr
211 NEURAPRO, a
double-blind,
placebo-controlled, randomized clinical tr
212 Rigorous
double-blind,
placebo-controlled, randomized controlled
213 A multinational, phase 3,
double-blind,
placebo-controlled, randomized withdrawal
214 We conducted a
double-blind,
placebo-controlled, randomized, fixed-dose
215 This phase 2, randomised,
double-blind,
placebo-controlled, single-centre, crossov
216 Using a randomized,
double-blind,
placebo-controlled, within-subject crossov
217 motivation in 21 healthy human subjects in a
double-blinded,
placebo (saline)-controlled, cross-over
218 icipants with mild asthma were enrolled in a
double-blinded,
placebo-controlled crossover study to as
219 A
double-blinded,
placebo-controlled randomized clinical t
220 Double-blinded,
placebo-controlled trial at 9 academic m
221 rican Region with Malaria) was a randomized,
double-blinded,
placebo-controlled trial conducted in ma
222 METHODS AND Randomized,
double-blinded,
placebo-controlled trial enrolled 31 pat
223 Patients and Methods In this
double-blinded,
placebo-controlled trial, patients with
224 ertiary HPS unit were randomly assigned in a
double-blinded,
placebo-controlled trial.
225 In this randomised,
double-blinded,
placebo-controlled, multiregional trial
226 We performed a
double-blinded,
placebo-controlled, parallel interventio
227 In this 1-year, randomised,
double-blinded,
placebo-controlled, phase 3 study (LIBER
228 METHODS AND We undertook a
double-blind randomised controlled trial of small-quanti
229 In this
double-blind randomised placebo-controlled trial, we enr
230 This was a multicentre,
double-blind,
randomised placebo-controlled trial for wh
231 In this multicentre,
double-blind,
randomised trial in seven Danish universit
232 In this phase 3, multinational,
double-blind,
randomised, controlled trial, adults (aged
233 DEPICT-1 was a
double-blind,
randomised, parallel-controlled, three-arm
234 EORTC 18071 was a multinational,
double-blind,
randomised, phase 3 trial in patients with
235 The phase 2,
double-blind,
randomised, placebo-controlled MERIT-1 tri
236 ion study in a pilot safety cohort, we did a
double-blind,
randomised, placebo-controlled trial based
237 For this
double-blind,
randomised, placebo-controlled trial, we e
238 We report two
double-blind,
randomised, placebo-controlled trials in a
239 We did this single-centre, 150-day,
double-blind,
randomised, placebo-controlled, crossover
240 out impeding other neutrophil functions in a
double-blind randomized clinical trial in healthy elders
241 In vitro results were confirmed in a
double-blind randomized clinical trial in healthy elders
242 E and Selenium (PREADViSE) trial began as a
double-blind randomized clinical trial in May 2002, whic
243 Trials Group Symptom Control Trial SC.23, a
double-blind randomized clinical trial that investigated
244 were eligible for inclusion if they were (1)
double-blind randomized clinical trials of DCS as an aug
245 The analysis included 167
double-blind randomized controlled trials with 28,102 ma
246 disease accrued between 2006 and 2010 to the
double-blind randomized placebo-controlled phase 3 trial
247 nrolled 10 SCA38 patients, and carried out a
double-blind randomized placebo-controlled study for 16
248 This was a
double-blind randomized sham controlled pilot study of t
249 en-label period, of whom 253 enrolled in the
double-blind randomized withdrawal period (127 in the pl
250 - to 16-week open-label period and a 26-week
double-blind randomized withdrawal period.
251 Multicenter,
double-blind,
randomized clinical trial including 500 pa
252 This parallel-design,
double-blind,
randomized clinical trial, called Resverat
253 up receiving a corn-soy blend.A prospective,
double-blind,
randomized controlled clinical trial was c
254 In a
double-blind,
randomized controlled trial, once-daily in
255 This
double-blind,
randomized crossover study addressed the i
256 intranasal oxytocin (24 IU) or placebo in a
double-blind,
randomized crossover study.
257 screened as anemic.In this 2 x 2 factorial,
double-blind,
randomized trial, nonpregnant women (aged
258 This multisite,
double-blind,
randomized within-patient study was conduc
259 We performed two similar,
double-blind,
randomized, 6-month phase 3 trials (Elaris
260 This
double-blind,
randomized, controlled trial investigates
261 mg (p.o.) and placebo over 2 test days in a
double-blind,
randomized, counterbalanced, cross-over de
262 Double-blind,
randomized, crossover noninferiority trial
263 f latitude and skin color.In a longitudinal,
double-blind,
randomized, food-based intervention study,
264 Multicenter,
double-blind,
randomized, parallel-group, phase 3 equiva
265 We conducted a
double-blind,
randomized, parallel-group, placebo-contro
266 Therefore, we conducted a
double-blind,
randomized, placebo-controlled crossover t
267 In this multicenter,
double-blind,
randomized, placebo-controlled study, 74 p
268 METHOD: A 12-week, prospective,
double-blind,
randomized, placebo-controlled trial (meth
269 In this prospective,
double-blind,
randomized, placebo-controlled trial condu
270 ress existing knowledge gaps, we conducted a
double-blind,
randomized, placebo-controlled trial to in
271 In this multicenter,
double-blind,
randomized, placebo-controlled trial, we a
272 Using a
double-blind,
randomized, placebo-controlled, parallel d
273 In this
double-blind,
randomized, placebo-controlled, phase 2 tr
274 ldren's Respiratory Initiative [TCRI]) and a
double-blinded,
randomized, controlled trial (MAKI), usi
275 We conducted a prospective,
double-blinded,
randomized, placebo-controlled, crossove
276 Patients who completed the 24-month
double-blind REFLEX (REbif FLEXible dosing in early MS)
277 ncephalic grafts as part of an NIH-sponsored
double-blind sham-controlled trial.
278 ignificant difference in response during the
double-blind,
sham-controlled phase (12 [20%] patients i
279 The trial was
double-blinded;
some unmasking took place at age 2 years
280 We performed a
double-blind study at 49 hospitals in Europe and Israel,
281 ER PFO Occluder to Medical Management) was a
double-blind study investigating migraine characteristic
282 In a randomized placebo-controlled
double-blind study of 162 HIV-negative RV144 vaccine rec
283 Phase 2 randomized, controlled,
double-blinded study of 4 antiretroviral regimens used a
284 Randomized,
double-blind,
treat-to-target crossover trial including
285 ne days from baseline to the last 4 weeks of
double-blind treatment (weeks 9-12).
286 Pooled data from 14 trials were analyzed (
double-blind treatment 8 to 104 weeks; n = 3,340 alirocu
287 ion >/= 30% from baseline for >/= 50% of the
double-blind treatment period, were observed in 20%, 44%
288 three times per day orally during a 12-week
double-blind treatment period.
289 pose LUME-Meso is a phase II/III randomized,
double-blind trial designed to assess efficacy and safet
290 , we conducted a single-center, prospective,
double-blind trial of 39 patients with mucinous-type pan
291 first large, randomized, placebo-controlled,
double-blind trial of a statin with standard-of-care for
292 ndred forty-six CAE children in a randomized
double-blind trial of ethosuximide, lamotrigine, and val
293 were recruited for a randomized, controlled,
double-blind trial of vitamin D supplementation in pregn
294 In this randomized,
double-blind trial, outpatients with schizophrenia (n=55
295 In a
double-blind trial, patients were randomized to tolvapta
296 In this
double-blind trial, we randomly assigned 2157 patients w
297 withdrawal, multicenter, placebo-controlled,
double-blind trial.
298 This parallel group, semirandomized
double-blinded trial was conducted in a single center in
299 at of a control.In a randomized, controlled,
double-blinded trial, 220 participants aged 18-60 y with
300 Among women participating in a randomized,
double-blinded trial, we assessed the effect of periodic